Azmiro is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 2 US drug patents filed from 2022 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 25, 2039. Details of Azmiro's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11642355 | Pharmaceutical compositions of testosterone |
Mar, 2039
(14 years from now) | Active |
| US11311554 | Pharmaceutical compositions of testosterone |
Mar, 2039
(14 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Azmiro is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Azmiro's family patents as well as insights into ongoing legal events on those patents.
Azmiro's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Azmiro's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 25, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Azmiro Generic API suppliers:
Testosterone Cypionate is the generic name for the brand Azmiro. 14 different companies have already filed for the generic of Azmiro, with Pfizer having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Azmiro's generic
About Azmiro
Azmiro is a drug owned by Azurity Pharmaceuticals Inc. Azmiro uses Testosterone Cypionate as an active ingredient. Azmiro was launched by Azurity in 2022.
Approval Date:
Azmiro was approved by FDA for market use on 02 June, 2022.
Active Ingredient:
Azmiro uses Testosterone Cypionate as the active ingredient. Check out other Drugs and Companies using Testosterone Cypionate ingredient
Dosage:
Azmiro is available in solution form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG/ML (200MG/ML) | SOLUTION | Prescription | INTRAMUSCULAR |